Literature DB >> 23301695

Prevalence and clinical significance of antithyroid antibodies in children with immune thrombocytopenic purpura.

Ali Bay1, Enes Coskun, Goksel Leblebisatan, Ozlem Karaoglu, Mehmet Keskin, Sibel Yavuz, Fatih Yilmaz, Alper Dai, Mehmet Yavuz Coskun.   

Abstract

BACKGROUND AND
OBJECTIVE: To determine the prevalence and the clinical significance of thyroid autoantibodies and their influence on treatment response in children with idiopathic thrombocytopenic purpura (ITP). PATIENT AND
METHOD: We retrospectively analyzed the antithyroglobulin (anti-TG) and antithyroid peroxidase (anti-TPO) antibodies from the records of 151 ITP patients who were admitted to the Pediatric Hematology Department of Gaziantep University between 2009 and 2012.
RESULTS: Anti-TPO and/or anti-TG was found positive in 38 (36.8%) of 103 patients whose thyroid autoantibody levels were measured. The comparison of positivity ratios of autoantibodies between acute and chronic ITP patients showed no significant difference. However, the separate comparison of each group of ITP patients with control group showed significantly high positivity ratios of autoantibodies in ITP patients. The initial mean platelet count of anti-TPO positive patients at diagnosis was significantly less than that of the negative patients (P = .008). One month after treatment, platelet count of anti-TPO positive patients was significantly less than that of the negative patients (P = .01). Moreover, the mean platelet counts of anti-TPO positive patients were significantly less than those of the negative patients after intravenous immunoglobulin treatment (P < .001).
CONCLUSION: We demonstrated that the thyroid-autoimmune-diseases-related autoantibodies are frequently found in childhood ITP. Although no recommendation is found in international guidelines regarding screening for thyroid autoantibodies in patients with ITP, in view of the high incidence of antithyroid antibodies and their potential negative effect on treatment response, screening these patients for such antibodies would be recommended.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23301695     DOI: 10.3109/08880018.2012.756564

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  4 in total

Review 1.  Clinical practice: immune thrombocytopenia in paediatrics.

Authors:  Veerle Labarque; Chris Van Geet
Journal:  Eur J Pediatr       Date:  2014-01-05       Impact factor: 3.183

2.  Markers of autoimmunity in immune thrombocytopenia: prevalence and prognostic significance.

Authors:  Marie A Hollenhorst; Hanny Al-Samkari; David J Kuter
Journal:  Blood Adv       Date:  2019-11-26

3.  Thyroid Dysfunction in Patients With Immune Thrombocytopenia: Prevalence and it's Impact On Outcome.

Authors:  Mukul Aggarwal; Manoranjan Mahapatra; Tulika Seth; Seema Tyagi; Nikhil Tandon; Renu Saxena
Journal:  Indian J Hematol Blood Transfus       Date:  2021-07-01       Impact factor: 0.900

4.  Chronic Immune Thrombocytopenia and Hashimoto's Hypothyroidism in an Adolescent: Presentation and Implications.

Authors:  Judy Ibrahim; Mohammad Alashqar; Shamma Al Zaabi; Omar Trad; Amar Al Shibli
Journal:  Case Rep Pediatr       Date:  2021-02-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.